Analyst firms · Wells Fargo · APLS

Wells Fargo APLS price target and rating history

Apellis Pharmaceuticals Inc. (APLS) · Health Care

Wells Fargo rates Apellis Pharmaceuticals Inc. (APLS) Overweight with a $32 price target, as of its latest action on Oct 15, 2025. It has published 5 rating actions on APLS since December 2021, including 1 upgrade and 2 downgrades. Across 3 firms with a APLS price target in the last 12 months, the median target is $28.

Current rating
Overweight
Price target
$32
Median target, all firms
$28
Actions on APLS
5

Wells Fargo price target on APLS

$84$58$3220222023202420252026
Wells Fargo price target on APLS, each point a stated target, December 2021 to October 2025.

Every Wells Fargo rating on APLS

How other firms rate APLS

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Roth CapitalBuy$31Mar 13, 2026
BarclaysEqual Weight$24Jan 28, 2026
BofA SecuritiesBuy$28Jan 21, 2026

Questions about Wells Fargo and APLS

What is Wells Fargo's price target for APLS?
Wells Fargo's latest stated price target for Apellis Pharmaceuticals Inc. (APLS) is $32, from its action on Oct 15, 2025.
What is Wells Fargo's rating on APLS?
Wells Fargo rates APLS Overweight, a bullish rating, as of Oct 15, 2025.
When did Wells Fargo last change its view on APLS?
On Oct 15, 2025, Wells Fargo starts coverage at Overweight, price target $32.
How does Wells Fargo's APLS target compare with other analysts?
Across 3 firms with a APLS price target in the last 12 months, the median target is $28.

More APLS rating histories

All Wells Fargo ratingsAPLS news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.